α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice - Aniszewska - 2022 - Brain and Behavior - Wiley Online Library
Parkinson's Study Finds New Compound that Can Inhibit Alpha-Synuclein
Distribution of α-Synuclein Aggregation in the Peripheral Tissues
Death-associated Protein Kinase 1 Phosphorylates α-Synuclein at Ser129 and Exacerbates Rotenone-induced Toxic Aggregation of α-Synuclein in Dopaminergic SH-SY5Y Cells
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Curcumin Interacts with α-Synuclein Condensates To Inhibit Amyloid Aggregation under Phase Separation
Alleviating toxic α-Synuclein accumulation by membrane depolarization: evidence from an in vitro model of Parkinson's disease, Molecular Brain
Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1
Novel and rapid device opens new doors for Pa
ISIS Studying the influence of salts on α-synuclein aggregation, a hallmark of Parkinson's disease
de
por adulto (o preço varia de acordo com o tamanho do grupo)
